By InvitationPhase 3

FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

Spain180 participantsStarted 2026-03-13

Plain-language summary

Study to demonstrate efficacy of finerenone when compared to placebo in reducing albuminuria in participants with chronic kidney disease (CKD) not using renin-angiotensin-system (RAS) inhibitors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults (≥18 years) with Chronic Kidney Disease defined as:
✓. Potassium level ≤5.0 mmol/L at Screening (local assessment).
✓. No current or previous (within 8 weeks prior to the Screening visit) treatment with RAS inhibition (ACEi, ARB, or Renin inhibitor (e.g. Aliskiren)).

Exclusion criteria

✕. Participants with an HbA1c\>11%.
✕. Participants with type 1 diabetes.
✕. Symptomatic heart failure with reduced ejection fraction and class 1A indication for MRA treatment.

What they're measuring

Urinary albumin-to-creatinine ratio (UACR)

Timeframe: Baseline upto 6 months

Trial details

NCT IDNCT07181135

SponsorUniversity Medical Center Groningen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-31

View on ClinicalTrials.gov More Chronic Kidney Disease trials